Clinical research on the effect of changing from denosumab to zoledronic acid (Multicenter collaborative retrospective observational research)

Clinical research on the effect of changing from denosumab to zoledronic acid (Multicenter collaborative retrospective observational research) - SM201901

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000037148

Enrollment

Registered

2019-06-28

Start date

2019-03-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteoporosis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Being a patient diagnosed with osteoporosis (2) Patients who are judged to be the most suitable Dmab for the treatment of osteoporosis (3) Being patient who can expect survival more than six months after administration of Dmab (4) Patients who are 20 years of age or older at the Dmab start date (5) Patients whose treatment after administration of Dmab is ZOL

Exclusion criteria

Exclusion criteria: (1) Patients undergoing treatment for malignancy (2) Patients with severe heart disease and cerebrovascular disease (3) Patients with serious diseases such as pancreas and blood (4) Patients with severe renal dysfunction or failure (for example, patients with eGFR (estimated glomerular filtration rate) less than 3.0 mL /min/1.73 m2, patients on dialysis) (5) In addition, patients that the research investigator or the doctor judged inappropriate for the target

Design outcomes

Primary

Measure	Time frame
Bone mineral density (Lumbar spine, Proximal femur total, Femoral neck)	—

Countries

Japan

Contacts

Public ContactToru Yoshioka

Shimura Hospital Orthopedics Department

t-yossy@rc4.so-net.ne.jp082-294-5151

Outcome results